$2.270
-0.030 (-1.30%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
XBIT Prediction & Forecast by Similar Chart Analysis
Alphio's XBIT stock price prediction model matches the current XBiotech Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.24 (-1.42%). The 1-week path is $2.18 (-3.92%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy XBiotech Inc Stock?
XBiotech Inc. is not a good buy right now due to significant ongoing losses and negative performance trends. The current price is $2.27, with a year-to-date change of -4.62% and a one-year change of -24.83%. The company reported a loss of $6.7 million in Q2 2026, which translates to a per-share loss of $0.22, indicating persistent financial challenges. The RSI is at 38.971, suggesting that the stock is nearing oversold territory but is not yet a buy signal. The main risk is the company's negative earnings trajectory, with a forward P/E of 0 and a price-to-sales ratio of 233.74, indicating overvaluation relative to sales.
XBIT stock price ended at $2.27 on Friday, after losing -1.30%
XBiotech Inc (XBIT) last closed at $2.27, losing -1.30%. These facts feed the 1-day and 1-week XBIT price prediction above.
Forecast Drivers
XBiotech Inc (XBIT) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Similar Chart Patterns
Stocks whose recent price path most closely matches XBIT, ranked by similarity.
Seasonality analysis for XBIT
Historically the probability of a positive August return for XBIT is 36.51%. May offers the highest probability of a positive month at 65.08%, while July is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.